Targeting RET alterations in non-small cell lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Rearranged during transfection (RET) proto-oncogene alterations activate oncogenic pathways in various cancers.
• RET fusions are found in 1-2% of non-small cell lung cancer (NSCLC) patients, driving tumor growth.
• Selective RET inhibitors (selpercatinib, pralsetinib) revolutionized NSCLC treatment after FDA approval in 2020.

Purpose of the Study:

• To review the biology of RET in NSCLC.
• To analyze clinical outcomes of RET inhibitors in NSCLC.
• To explore challenges and future directions in overcoming RET inhibitor resistance.

Main Methods:

• Literature review of RET biology, testing methods, and clinical trial data.
• Analysis of mechanisms of on-target and off-target RET resistance.
• Synthesis of current and future therapeutic strategies for RET-altered NSCLC.

Main Results:

• First-generation RET inhibitors are standard care for RET-fusion positive NSCLC.
• Acquired resistance to RET inhibitors is a growing clinical challenge.
• Understanding resistance mechanisms is crucial for developing next-generation therapies.

Conclusions:

• RET alterations are key targets in NSCLC, with inhibitors showing significant efficacy.
• Overcoming acquired resistance is paramount for long-term patient benefit.
• Ongoing research and clinical trials are vital for advancing RET-targeted therapy in NSCLC.